Doloromicsis a seed-stage startup developing novel therapeutics to treat chronic pain. The team at Doloromicshas built a proprietary computational platform to identify drug targets within the human Dorsal Root Ganglion (DRG). Through a collaboration with NanoString, the company deeply sequenced and transcriptomically profiled nociceptors to uncover moderate-to-low expressed drug targets that would typically be overlooked by traditional sequencing methods. The results demonstrated by the team illuminate the ways in which the GeoMx® Digital Spatial Profiling platform can be used to facilitate an approach to precision medicine.
Utilizing Spatial Transcriptomics to Unlock Precision Pain Therapeutics
30 June 2022, 6:00:00 am
Jackson Brougher, Ph.D
Chief Scientific Officer